Skip to main content
. 2019 Sep 27;98(39):e17216. doi: 10.1097/MD.0000000000017216

Figure 1.

Figure 1

Aberrant expression of LTBP2 in HCC patients. (A) The mRNA expression levels of LTBP2 determined by qRT-PCR in HCC tissues (n = 60) and adjacent nontumor tissues (n = 60); (B) Photographs of LTBP2 immunohistochemical staining in HCC tissues and adjacent non-tumor tissues; (C) The serum LTBP2 levels in patients with HCC and normal controls (n = 60) using ELISA; (D) Kaplan–Meier curves of survival rate differed between high and low LTBP2 expression in HCC patients. ∗∗P < .01 versus adjacent nontumor tissues; #P < .05 versus normal controls. ELISA = enzyme-linked immunosorbent assay, HCC = hepatocellular carcinoma, LTBP2 = latent TGF-β binding protein 2, mRNA = messenger RNA, qRT-PCR = quantitative real time polymerase chain reaction.